New biomedreports just out w/link
Shares of Adventrx Pharmaceuticals, Inc. (AMEX:ANX) dipped down to below thirty cents again on Thursday after having risen to a high of over fifty cents earlier this month when the company announced an NDA filing for ANX-530. The news of the NDA was followed by a stock offering.
ADVENTRX PHARMACEUTICALS, Inc.
0.28 +0.00 (+0.11%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
Those looking to speculate on the ANX-530 position could be looking at a nice entry point, in my opinion, below thirty cents. I feel we'll see at least fifty cents again before the FDA decision is announced - maybe more, depending on the market.
Buy the dips and play the volatility here, in my position.
Vinny Cassano also authors the popular biotech stock blog VFC's Stock House. He is long ANX, BMSN and SIGA
News 
Market Data 
Discover 
AI
